RSS Feeds
Severe Neutropenia and Thrombocytopenia Associated with Infliximab
- Francesc Vidal, MD, PhD;
- Ramón Fontova, MD, PhD; and
- Cristóbal Richart, MD, PhD
- Hospital Universitari Joan XXIII, Universitat Rovira i Virgili; 43007 Tarragona, Spain (Vidal, Fontova, Richart)
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Infliximab, a monoclonal anti–tumor necrosis factor (TNF)-α antibody, has recently been approved for treatment of rheumatoid arthritis (1, 2). To date, therapy with this drug has been associated with few adverse events (3-5).
Objective: To describe …
This 100-word excerpt has been provided in the absence of an abstract.
